Kling Biotherapeutics has dosed the first subject in its Phase Ib KBA1412-101 clinical trial of antibody KBA1412 in adults with advanced solid tumours unresponsive to standard of care.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,